Learn More
Two chimeric human/murine monoclonal antibodies were constructed by substitution of the murine constant regions with human γ1 and κ constant regions for heavy and light chains, respectively. The chimeric human/murine molecules are anti-idiotypic antibodies, meaning that they were directed against the antigen binding site in the variable region of another(More)
BACKGROUND Personalized medicine technologies can improve individual health by delivering the right dose of the right drug to the right patient at the right time but create challenges in deciding which technologies offer sufficient value to justify widespread diffusion. Personalized medicine technologies, however, do not neatly fit into existing health(More)
OBJECTIVE The effectiveness of treatment decisions and economic outcomes of using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (Gd-EOB-DTPA-MRI) were compared with extracellular contrast media-enhanced MRI (ECCM-MRI) and multi-detector computed tomography (MDCT) as initial procedures in patients with(More)
It is estimated that 5.7% of American adults, or approximately 14.5 million people, are morbidly obese, defined as a body mass index (BMI) of >40 kg/m2 and thus are eligible for bariatric surgery. (Flegal et al. 2010) If in one year, only 10% of these morbidly obese patients (approximately 1.45 Million) would undergo bariatric surgery, with an average(More)
OBJECTIVE To evaluate prior analyses that quantify how drug management programs impact health plans and patients with respect to those analyses' effectiveness in measuring program quality. METHODS We examined 77 US studies from 1996 to 2007 that evaluated the respective drug management programs of managed care, indemnity insurance, Veterans Health(More)
BACKGROUND Maintaining quality of care while managing limited healthcare resources is an ongoing challenge in healthcare. The objective of this study was to evaluate how the impact of drug management programs is reported in the literature and to identify potentially existing quality standards. METHODS This analysis relates to the published research on the(More)
BACKGROUND Health economics and outcomes research (HEOR) is a growing field that provides important information for making healthcare coverage and access decisions. However, there is no standard process for incorporating HEOR into the decision-making process, and the current use of HEOR by healthcare payers remains unknown. OBJECTIVES To examine how HEOR(More)
This report summarizes a roundtable discussion of managed care experts and academic pharmacoeconomists, held in March 2008 with the objective of defining action steps to overcome barriers to the incorporation of real-world data into health care decision making. The roundtable meeting was the result of an initial program in July 2007 where managed care(More)